References
  1. Verluys AB, Bresters D. Pulmonary complications of childhood cancer treatment. Paediatric Respiratory Reviews 2017; 17: 63-70.
  2. Ewig S, Torres A, Riquelme R, El-Ebiary M, Rovira M, Carreras E, Raño A, Xaubet A. Pulmonary complications in patients with haematological malignancies treated at a respiratory ICU. Eur Respir J 1998; 12: 116-22.
  3. Elbahlawan L, Rains KJ, Stokes DC. Respiratory care considerations in the childhood cancer patient. Respir Care 2017; 62: 765-775.
  4. Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: The Children’s Oncology Group Long-Term Follow-Up Guidelines from the Children’s Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004; 22: 4979-4990.
  5. Segura A, Yuste A, Cercos A, et al. Pulmonary fibrosis induced by cyclophosphamide. Ann Pharmacother 2001; 35: 894–7.
  6. Usemann J, Yammine S, Singer F, Latzin P. Inert gas washout: Background and application in various lung diseases. Swiss Med Wkly 2017; 16: 147.
  7. Aurora P, Bush A, Gustafsson P, Oliver C, Wallis C, Price J, et al. London Cystic Fibrosis Collaboration. Multiple-breath washout as a marker of lung disease in preschool children with cystic fibrosis. Am J Respir Crit Care Med 2005; 171: 249–56
  8. Hjalmarson O, Sandberg K. Abnormal lung function in healthy preterm infants. Am J Respir Crit Care Med 2002; 165: 83–7.
  9. Fowler WS, Cornish ER, Jr, Kety SS. Lung function studies. VIII. Analysis of alveolar ventilation by pulmonary N2 clearance curves. J Clin Invest 1952; 31(1): 40–50.
  10. Robinson PD, Latzin P, Verbanck S, Hall GL, Horsley A, Gappa M, et al. Consensus statement for inert gas washout measurement using multiple- and single-breath tests. Eur Respir J 2013; 41: 507–22.
  11. Robinson PD, Latzin P, Ramsey KA, et al. Preschool Multiple-Breath Washout Testing. An Official American Thoracic Society Technical Statement. Am J Respir Crit Care Med 2018; 197: e1–e19.
  12. Jensen R, Stanojevic S, Klingel M, et al. A systematic approach to multiple breath nitrogen washout test quality. PloS One 2016; 11: e0157523 10.1371/journal.pone.0157523
  13. Lum S, Stocks J, Stanojevic S, et al. Age and height dependence of lung clearance index and functional residual capacity. Eur Respir J 2013; 41: 1371-1377.
  14. Beydon N, Davis SD, Lombardi E, et al. An official American Thoracic Society/European Respiratory Society statement: Pulmonary function testing in preschool children. Am J Respir Crit Care Med 2007; 175: 1304-1345.
  15. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338.
  16. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: The global lung function 2012 equations. Eur Respir J 2012; 40: 1324-1343.
  17. Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res 2012; 13: 39.
  18. Dietz AC, Chen Y, Yasui Y, et al. Risk and impact of pulmonary complications in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer 2016; 122: 3687-3696.
  19. Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration 2004; 71: 301-26.
  20. Myers JL, Limper AH, Swensen SJ. Drug-induced lung disease: A pragmatic classification incorporating HRCT appearances. Semin Respir Crit Care Med 2003; 24: 445-54.
  21. Silva CI, Müller NL. Drug-induced lung diseases: most common reaction patterns and corresponding high-resolution CT manifestations. Semin Ultrasound CT MR 2006; 27: 111-6.
  22. Pietra GG. Pathologic mechanisms of drug-induced lung disorders. J Thorac Imaging 1991; 6(1): 1-7.
  23. Eigen H, Wyszomierski D. Bleomycin lung injury in children. Pathophysiology and guidelines for management. Am J Pediatr Hematol Oncol 1985; 7: 71–8.
  24. Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001; 120: 617–24.
  25. Mulder RL, Thonissen NM, van der Pal HJ, et al. Pulmonary function impairment measured by pulmonary function tests in long-term survivors of childhood cancer. Thorax 2011; 66: 1065–1071.
  26. Landier W, Armenian SH, Lee J, et al. Yield of screening for long-term complications using the children’s oncology group long-term follow-up guidelines. J Clin Oncol 2012; 30: 4401-8.
  27. Hudson MM, Ness KK, Gurney JG, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA 2013; 309: 2371-2381.
  28. Armenian SH, Landier W, Francisco L, et al. Long-term pulmonary function in survivors of childhood cancer. J Clin Oncol 2015; 33: 1592-600.
  29. Dietz AC, Chen Y, Yasui Y, et al. Risk and impact of pulmonary complications in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer 2016; 122: 3687-3696.
  30. Nysom K, Holm K, Olsen JH, Hertz H, Hesse B. Pulmonary function after treatment for acute lymphoblastic leukaemia in childhood. Br J Cancer 1998; 78: 21-27.
  31. Miller RW , Fusner JE , Fink RJ, et al. Pulmonary function abnormalities in long-term survivors of childhood cancer. Med Pediatr Oncol 1986; 14: 202-207.
  32. Jenney ME , Faragher EB , Jones PH , Woodcock A. Lung function and exercise capacity in survivors of childhood leukaemia. Med Pediatr Oncol 1995; 24: 222-230.